-

Incyte Investor Conference Update

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) has updated its presentation time at the following investor conference:

  • JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT).

The presentation at the BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 p.m. (EDT) is unchanged.

The presentations for both conferences will be webcast live and can be accessed at Investor.Incyte.com. Replays will be available for 30 days.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Media
Catalina Loveman, +1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com

Incyte

NASDAQ:INCY

Release Summary
Incyte Investor Conference Update.
Release Versions
$Cashtags

Contacts

Media
Catalina Loveman, +1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com

Social Media Profiles
More News From Incyte

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis...

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates...
Back to Newsroom